PhytoHealth Corporation Reports Earnings Results for the Month and First Quarter Ended May 2015
Jun 12 15
PhytoHealth Corporation reported earnings results for the month and first quarter ended May 2015. For the month, the company reported revenue of TWD 1.75 million. Pre-tax loss was TWD 20.60 million. Net loss was TWD 20.60 million or TWD 0.13 per share.
For the quarter, the company reported revenue of TWD 4.78 million. Pre-tax loss was TWD 82.31 million. Net loss was TWD 82.30 million or TWD 0.43 per share.
Phytohealth Corporation Provides Current R&D progress on PG2 Injection 500 Mg, Anti-Tussive, Anti-Osteoporosis, and Anti-Vertigo New Drugs
Feb 26 15
PhytoHealth Corporation provided current R&D progress on PG2 Injection 500mg. The company made an announcement on the R&D progress of the four new drugs currently in development. New drug in development#1: PG2 Injection 500mg. The API of PG2 Injection 500mg is in steady production at the company’s Botanical New Drug Refining Plant; currently, the company takes a very active role in promoting PG2 into the formulary of major hospitals. PG2 Injection 500mg, which is indicated for the un-recoverable moderate to severe fatigue syndrome during the course of cancer treatment, has received NDA approval from TFDA for market sale. Clinical trial for treating ischemic stroke: Trial Title: PG2 Injection 500mg for Acute Stroke Study Institution: Fifteen medical centers, including NTUH and CMUH. Trial Update: The study is the achievement of an industry-academia collaboration with CMUH's Stroke Clinical Trials and Research Center of Excellence, via the purposely established Industry-Academia Link Innovative Research Office. Currently, the study has received IRB approval from two branches of CMUH, KMUH, CHGH, KTGH, SKH, NTUH, TVGH Taipei, TVGH Kaohsiung, TSGH, ECKH, NCKUH, WFH, SHH and CCH, and the study has completed 24% patient enrollment. The company continues to actively recruiting trial subjects. Clinical trial for treating hemorrhagic stroke: Trial Title: PG2 Injection 500mg for Spontaneous IntracerebralHemorrhage Pilot Study. Institution: China Medical University Hospital. Trial Update: The study is the achievement of co-established Industry-Academia Link Innovative Research Office with CMU. The trial was completed and the result was publicized in Asia Pacific Stroke Conference 2014. Currently the company has started planning the next phase of clinical trials. New drug in development #2: Anti-tussive. Clinical trial for treating acute cough: Trial Title: PDC-748 for Acute Cough Phase II Study. Institution: CGMH, CMUH and BTCGH. Trial Update: The company is currently conducting a risk and benefit assessment based on Phase II study results. New drug in development #3: Anti-oteoporosis. Clinical trial for preventing osteoporosis: Trial Title: PH3 for the Prevention of Osteoporosis in Post- menopausal Women in Phase II, Double-Blind, Randomized, and Placebo Controlled Study. Institution: TVGH, CGMH, NTUH and MMH. Trial Update: Phase II clinical study was completed. The company continues to assess the compatibility of clinical trial regulations between Taiwan and China, in response to being selected as a pilot project for TFDA's cross-strait cooperation. New drug in development #4: Anti-vertigo. Clinical trial for bio-availability and pharmacokinetics: Trial Title: Phencynonate Hydrochloride for Bio-availability, Pharmacokinetics and Safety in Healthy Subjects Study. Institution: Tri-Service General Hospital.Trial Update: Bio-availability and pharmacokinetics study was completed. The company is assessing the risk and benefit for subsequent development.
PhytoHealth Corporation, Annual General Meeting, Jun 03, 2015
Feb 24 15
PhytoHealth Corporation, Annual General Meeting, Jun 03, 2015. Location: 3rd Fl., No.10 Shih-er Rd. Agenda: To consider the 2014 business report; to consider the 2014 supervisor’s review report; to consider the status report on the execution of plans to enhance operations for 2012 capital increase through cash injection; to consider the report on amendment to the corporate social responsibility best practice principles and ethical corporate management best practice principles; to consider the report on codes of ethical conduct; to consider the adoption of 2014 the individual and consolidated financial statements and business report; and to consider the adoption 2014 loss be subsidized, and in the case of capital reserves to make up for the accumulated losses.